CN107596370A - A kind of drug compound preparation and purposes for treating cervical erosion - Google Patents
A kind of drug compound preparation and purposes for treating cervical erosion Download PDFInfo
- Publication number
- CN107596370A CN107596370A CN201711011143.2A CN201711011143A CN107596370A CN 107596370 A CN107596370 A CN 107596370A CN 201711011143 A CN201711011143 A CN 201711011143A CN 107596370 A CN107596370 A CN 107596370A
- Authority
- CN
- China
- Prior art keywords
- drug compound
- compound preparation
- ala
- ulcerlmin
- polyphenol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present invention relates to a kind of drug compound preparation and purposes for treating cervical erosion, the effective active composition of the drug compound preparation is Resina Draconis polyphenol, ulcerlmin and 5 aminolevulinic acids or derivatives thereof.Resina Draconis polyphenol, ulcerlmin and 5 aminolevulinic acids or derivatives thereof joint are used as active constituents of medicine by the present invention, using topical therapy cervical erosion, achieve the effect of unexpected.
Description
Technical field
The invention belongs to pharmaceutical technology field, and in particular to a kind of drug compound preparation and purposes for treating cervical erosion.
Background technology
Cervical erosion is a kind of most common lesion of gynecological clinic, be uterine cervical squamous epithelium because infection or wound (as point
Childbirth) stimulation and denude, a kind of and disease replaced by columnar epithelium.The easy inflammation in cervical erosion region, and often result in
Menstrual period guiding secretion increase.Importantly, cervical erosion needs early treatment to prevent possible pernicious change.It is actual
On, treat if inappropriate, cervical erosion easilys lead to cervix cancer, and according to statistics, women is because in death caused by cancer, about
10% is that cervix cancer is brought.
Cervical erosion typically uses surgical operation therapy, typically inustion, electrocoagulation or cryosurgery.Surgical operation is treated
Method can destroy infected tissue, and epithelial cell is then formed by fibroblast proliferation and again to fully recover.But the above method
The risk for being pregnant or having difficult labour after postoperative hemorrhage, infection, stenosis of cervix, influence may be brought.
Another treatment method of cervical erosion is drug therapy, and drug therapy is based on local treatment, but serious palace
Neck is rotten to the corn poor using local application's curative effect, and urgent need research is a kind of to answer for the medicine that serious cervical erosion has more preferable curative effect
Square preparation.
The content of the invention
In order to solve the above problems, the invention provides a kind of drug compound preparation and use for being used to treat cervical erosion
On the way, the drug compound preparation can solve the problems, such as that current topical medications curative effect is poor.
The technical scheme that the present invention takes is as follows：
One aspect of the present invention provides a kind of drug compound preparation, and the effective active composition of the drug compound preparation is dragon
Dragon's blood polyphenol, ulcerlmin and 5-ALA or derivatives thereof.
Further, in terms of parts by weight, in the drug compound preparation, Resina Draconis polyphenol is 0.5-10 parts, ulcerlmin
For 10-25 parts, 5-aminolevulinic acid or derivatives thereof 20-50 parts.
Further, the 5-ALA derivative is selected from ALA, 5-ALA sulphur
One kind in hydrochlorate, 5-ALA succinate, 5-ALA methyl esters or the own ester of 5-ALA.
Further, the formulation of the drug compound preparation is solution, suppository or gel.
Further, the gel for the effective active composition is mixed with gel-type vehicle, auxiliary material and deionized water and
Into.
Further, the gel-type vehicle is selected from hydroxymethyl cellulose, carbomer, chitosan derivatives, polycarbophil, wood
One or more in sugared glucan or sodium alginate.
Further, the auxiliary material is in thickener, antioxidant, stabilizer, surfactant, preservative or antiseptic
One or more.
Further, the preparation is vagina administration preparation or rectally preparation.
Present invention also offers a kind of drug compound preparation as described above answering in treatment cervical erosion medicine is prepared
With.
In the drug compound preparation of the present invention, Resina Draconis polyphenol has promoting blood circulation to remove blood stasis, analgesic therapy hemostasis, holds back wound promoting muscle growth functions.
Proliferation, Differentiation and the secretion of Skin Cell can also be promoted, and promote capillary to regenerate, blood supply increase, and then promotion organization
Reparation of the engineering skin to skin wound.Resina Draconis polyphenol, which is applied, to be spread at the local erosion of uterine neck, can provide energy for human body cell,
The normal function of human body cell is maintained, and can suppresses the breeding of common microbiological, dies of hunger bacterium.
In the drug compound preparation of the present invention, ulcerlmin is the amorphous state complex compound of sucrose sulfuric ester and aluminium hydroxide, right
Ulcer spot has special affinity, and the gel for preventing that pepsin from damaging, therefore mesh are formed by being combined with mucoprotein
It is preceding to be used as cell-protecting in treatment gastric ulcer and chronic gastritis.It is reported that ulcerlmin can also be used locally for preventing and controlling
Treat skin or mucomembranous surface inflammation and/or infection.Also have been reported that and show that ulcerlmin can be treated caused by bacterium and virus infection
Inflammation and vaginopathy, the infection as caused by herpes simplex virus, mycoplasma, Chlamydia, candida albicans, trichomonad etc., and treatment and pre-
Inflammation caused by anti-cervical atypism hyperplasia and cancer.
In the drug compound preparation of the present invention, 5-aminolevulinic acid and its derivative are conventional Visudynes,
Product through listing includes ALA, 5-ALA methyl esters and the own ester of 5-ALA.Into people
Haematoporphyrin is converted into after body and is detained in vivo, active oxygen such as singlet oxygen and other freedom are produced after the illumination of specific wavelength
Base simultaneously kills pathogenic cell (cancer cell, the cell of human papilloma virus and herpes simplex infections, wart body cell), and faces
Near normal tissue cell is not affected.Clinically 5-aminolevulinic acid and its derivative are used to treating acne, sharp wet
A variety of diseases such as the epithelial squamous cell knurl sample of wart, actinic keratoma, cervical carcinoma and vagina and uterus neck change.
The present invention by Resina Draconis polyphenol, ulcerlmin and 5-aminolevulinic acid or derivatives thereof joint be used as pharmaceutical activity into
Point, using topical therapy cervical erosion, achieve the effect of unexpected.
Embodiment
Embodiments of the present invention are described in detail below with reference to embodiment, and illustrated embodiment is served only for explaining this hair
It is bright, it is not intended to limit the scope of the present invention.
The experimental method of unreceipted actual conditions in the following example, generally according to normal condition, or according to manufacturer
Proposed condition.
Involved medicine or auxiliary material are commercial goods in the following example.
Embodiment 1
Formula composition：Resina Draconis polyphenol 10g, ulcerlmin 20g, ALA acid sodium 45g, carbomer 1g, to hydroxyl
Yl benzoic acid methyl esters 0.08g, triethanolamine 0.1g, propane diols 0.4g, deionized water add to 100g.
Preparation process：Weigh carbomer 1g and be scattered in 60g deionized waters and be swelled 24h, add triethanolamine and adjust pH value
To 4.0-5.0, solution A is obtained；With appropriate warm water dissolving methyl p-hydroxybenzoate 0.08g, propane diols 0.4g, Resina Draconis polyphenol
10g, ulcerlmin 20g, ALA acid sodium 45g, and be slowly added into solution A, addition deionized water to 100g, stirring
Uniformly produce medicament gelling agent.
Embodiment 2
Formula composition：Resina Draconis polyphenol 8g, ulcerlmin 15g, ALA acid sodium 35g, carbomer 0.7g, to hydroxyl
Yl benzoic acid methyl esters 0.06g, triethanolamine 0.1g, propane diols 0.3g, deionized water add to 100g.
Preparation process：Weigh carbomer 0.7g and be scattered in 50g deionized waters and be swelled 24h, add triethanolamine and adjust pH
Value obtains solution A to 4.0-5.0；With appropriate warm water dissolving methyl p-hydroxybenzoate 0.06g, propane diols 0.3g, Resina Draconis polyphenol
8g, ulcerlmin 15g, ALA acid sodium 35g, and be slowly added into solution A, addition deionized water to 100g, stirring
Uniformly produce medicament gelling agent.
Embodiment 3
Formula composition：Resina Draconis polyphenol 5g, ulcerlmin 10g, ALA acid sodium 20g, carbomer 0.5g, to hydroxyl
Yl benzoic acid methyl esters 0.04g, triethanolamine 0.1g, propane diols 0.2g, deionized water add to 100g.
Preparation process：Weigh carbomer 0.5g and be scattered in 40g deionized waters and be swelled 24h, add triethanolamine and adjust pH
Value obtains solution A to 4.0-5.0；With appropriate warm water dissolving methyl p-hydroxybenzoate 0.04g, propane diols 0.2g, Resina Draconis polyphenol
5g, ulcerlmin 10g, ALA acid sodium 20g, and be slowly added into solution A, addition deionized water to 100g, stirring
Uniformly produce medicament gelling agent.
Comparative example 1
Formula composition：Resina Draconis polyphenol 10g, carbomer 1g, methyl p-hydroxybenzoate 0.08g, triethanolamine 0.1g, third
Glycol 0.4g, deionized water add to 100g.
Preparation process：Weigh carbomer 1g and be scattered in 60g deionized waters and be swelled 24h, add triethanolamine and adjust pH value
To 4.0-5.0, solution A is obtained；With appropriate warm water dissolving methyl p-hydroxybenzoate 0.08g, propane diols 0.4g, Resina Draconis polyphenol
10g, and be slowly added into solution A, addition deionized water stirs to 100g and produces medicament gelling agent.
Comparative example 2
Formula composition：Ulcerlmin 20g, carbomer 1g, methyl p-hydroxybenzoate 0.08g, triethanolamine 0.1g, propane diols
0.4g, deionized water add to 100g.
Preparation process：Weigh carbomer 1g and be scattered in 60g deionized waters and be swelled 24h, add triethanolamine and adjust pH value
To 4.0-5.0, solution A is obtained；With appropriate warm water dissolving methyl p-hydroxybenzoate 0.08g, propane diols 0.4g, ulcerlmin 20g, and
It is slowly added into solution A, addition deionized water stirs to 100g and produces medicament gelling agent.
Comparative example 3
Formula composition：ALA acid sodium 45g, carbomer 1g, methyl p-hydroxybenzoate 0.08g, three ethanol
Amine 0.1g, propane diols 0.4g, deionized water add to 100g.
Preparation process：Weigh carbomer 1g and be scattered in 60g deionized waters and be swelled 24h, add triethanolamine and adjust pH value
To 4.0-5.0, solution A is obtained；With appropriate warm water dissolving methyl p-hydroxybenzoate 0.08g, propane diols 0.4g, 5-ALA
Hydrochloric acid sodium 45g, and be slowly added into solution A, addition deionized water stirs to 100g and produces medicament gelling agent.
Experimental example
25-45 year women of multidigit gynecatoptron analysis showed different cervical erosion is chosen, before start of the treatment, is adopted
Analyze each patient's cervical erosion degree with gynecatoptron, according to gynecatoptron photo and may with inflammation seriousness, to by
Examination patient is classified according to routine cervical pathological classification, and hierarchy plan is as follows：
1st grade：, there is mottled disease damage and dystopy in pure cervicitis, leukorrhea is reduced, without dyspareunia (sexual intercourse
When allodynic)；
2nd grade：, the epithelium changed be present in Cervicitis with erosion Extensive site (30% surface)：Accident hemorrhage and
Accidental dyspareunia；
3rd level：, dystopy, frequent bleeding, leukorrhea and sexual intercourse be present in Cervicitis with erosion Extensive site (50% surface)
It is difficult.
After classification, be divided into by classification results 1 grade in 6 groups, every group, 2 grades, 3 grades of patients be 10 people, wherein the 1st group is applied
The medicament gelling agent prepared with embodiment 1, the 2nd group is applied medicament gelling agent prepared by embodiment 2, and the 3rd group is made using embodiment 3
Standby medicament gelling agent, the 4th group is applied medicament gelling agent prepared by comparative example 1, is applied medicine prepared by comparative example 2 for the 5th group and is coagulated
Jelly, the 6th group is applied medicament gelling agent prepared by comparative example 3.Each patient daily in night medication once, continuous use six
My god.After local treatment terminates, each patient's cervical erosion degree is analyzed again using gynecatoptron.
Test result is as shown in table 1：
The vaginoscopy result of table 1
As it can be seen from table 1 use the combination medicine compound preparation of the present invention, patient's cervix erosion degree after the treatment
Substantially reduce, 1 grade of patient numbers is increased to 22 people, 20 people and 18 people respectively by 10 original people, and 3 grades of erosion patients are by original
10 people are reduced to 1 people, 2 people and 4 people respectively.And only with ulcerlmin, Resina Draconis polyphenol or ALA activity
Component, 1 grade of patient increases number and 3 grades of patients reduce number less than the present invention, illustrates that the drug compound preparation of the present invention exists
There is extraordinary curative effect in terms for the treatment of cervical erosion.
The foregoing is only presently preferred embodiments of the present invention, be not intended to limit the invention, it is all the present invention spirit and
Within principle, any modification, equivalent substitution and improvements made etc., it should be included in the scope of the protection.
Claims (9)
- A kind of 1. drug compound preparation, it is characterised in that the effective active composition of the drug compound preparation be Resina Draconis polyphenol, Ulcerlmin and 5-ALA or derivatives thereof.
- 2. drug compound preparation according to claim 1, it is characterised in that in terms of parts by weight, the medicaments compound system In agent, Resina Draconis polyphenol is 0.5-10 parts, ulcerlmin is 10-25 parts, 5-aminolevulinic acid or derivatives thereof 20-50 parts.
- 3. drug compound preparation according to claim 1 or 2, it is characterised in that the 5-ALA derivative choosing From ALA, 5-ALA sulfate, 5-ALA succinate, 5-ALA methyl esters Or one kind in the own ester of 5-ALA.
- 4. drug compound preparation according to claim 1, it is characterised in that the formulation of the drug compound preparation is solution Agent, suppository or gel.
- 5. drug compound preparation according to claim 4, it is characterised in that the gel is the effective active composition Mixed with gel-type vehicle, auxiliary material and deionized water.
- 6. drug compound preparation according to claim 5, it is characterised in that the gel-type vehicle is selected from hydroxylmethyl cellulose One or more in element, carbomer, chitosan derivatives, polycarbophil, xyloglucan or sodium alginate.
- 7. drug compound preparation according to claim 5, it is characterised in that the auxiliary material is thickener, antioxidant, steady Determine the one or more in agent, surfactant, preservative or antiseptic.
- 8. according to the drug compound preparation described in claim any one of 4-7, it is characterised in that the preparation is vagina administration system Agent or rectally preparation.
- 9. the drug compound preparation as described in claim any one of 1-8 is preparing the application in treating cervical erosion medicine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711011143.2A CN107596370A (en) | 2017-10-26 | 2017-10-26 | A kind of drug compound preparation and purposes for treating cervical erosion |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711011143.2A CN107596370A (en) | 2017-10-26 | 2017-10-26 | A kind of drug compound preparation and purposes for treating cervical erosion |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107596370A true CN107596370A (en) | 2018-01-19 |
Family
ID=61079932
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201711011143.2A Withdrawn CN107596370A (en) | 2017-10-26 | 2017-10-26 | A kind of drug compound preparation and purposes for treating cervical erosion |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107596370A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112618596A (en) * | 2021-01-19 | 2021-04-09 | 山东百奥生物医药有限公司 | Bacteriostatic and antiviral gel capable of observing focus area and preparation method and application thereof |
| WO2022175899A1 (en) * | 2021-02-19 | 2022-08-25 | Vanessa Research, Inc. | Compositions and methods for treating diseases associated with drug washout due to fluid secretion |
-
2017
- 2017-10-26 CN CN201711011143.2A patent/CN107596370A/en not_active Withdrawn
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112618596A (en) * | 2021-01-19 | 2021-04-09 | 山东百奥生物医药有限公司 | Bacteriostatic and antiviral gel capable of observing focus area and preparation method and application thereof |
| WO2022175899A1 (en) * | 2021-02-19 | 2022-08-25 | Vanessa Research, Inc. | Compositions and methods for treating diseases associated with drug washout due to fluid secretion |
| US20230398136A1 (en) * | 2021-02-19 | 2023-12-14 | Vanessa Research, Inc. | Compositions and methods for treating diseases associated with drug washout due to fluid secretion |
| US12064443B2 (en) * | 2021-02-19 | 2024-08-20 | Vanessa Research Holdings, Inc. | Compositions and methods for treating diseases associated with drug washout due to fluid secretion |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108348577B (en) | Mussel mucin product and application thereof in inhibiting skin inflammation | |
| DK169018B1 (en) | Use of sulphated sugar species | |
| MXPA00009705A (en) | The use of polyamines in the treatment of dermatological symptoms. | |
| CN103182070B (en) | External composition, and preparation and application thereof | |
| US4708873A (en) | Method of chemically debriding uncerated necrotic tissue | |
| CN1226037C (en) | Use of sucralfate for the treatment of cervical erosion | |
| CN107596370A (en) | A kind of drug compound preparation and purposes for treating cervical erosion | |
| US20140348873A1 (en) | Urea-Silicone Gel for Hyperkeratosis Treatment | |
| US20210236446A1 (en) | Wound healing composition | |
| US20140350106A1 (en) | Urea Silicone Gel for Scars and Hydration Treatment and Method of Using Same | |
| CN112933214A (en) | Composition for promoting wound healing | |
| CN106794140A (en) | Pharmaceutical composition based on active material stablizing solution | |
| CN102240260B (en) | Medicament for treating colpoxerosis and preparation method thereof | |
| CN107854471A (en) | A kind of pharmaceutical preparation and purposes for treating cervical erosion | |
| CN107582806A (en) | A kind of pharmaceutical composition and purposes for treating cervical erosion | |
| CN102641277B (en) | Ointment for treating gynaopathy and dermatoses and preparation method thereof | |
| CN106075001A (en) | Water-soluable gel containing Sanguis Draxonis polyphenol and the purposes on treatment cervical erosion medicine thereof | |
| CN101837068B (en) | Preparation process of zanthoxylum oil spray and application thereof | |
| CN112316108A (en) | Compositions and methods for promoting and treating chronic wound healing | |
| CN110882235A (en) | Breast nodule eliminating cataplasm and its preparation method | |
| CN110433284A (en) | A kind of composition that treating cervicitis, gelling agent and preparation method thereof | |
| CN100496508C (en) | Policresulen gelling agent, method for preparation the same and the pharmaceutical use thereof | |
| CN107583050A (en) | A kind of pharmaceutical composition and purposes for being used to treat cervicitis | |
| CN105168632A (en) | Traditional Chinese medicinal plastics for promoting healing of wound of cesarean section and preparation method thereof | |
| CN103520707B (en) | A kind of beneficial bacterium controls the compositions that bacterium prevention and therapy gynaecologic reproductive system infects |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20180119 |
|
| WW01 | Invention patent application withdrawn after publication |